Libtayo® (Cemiplimab) 获欧盟 CHMP 推荐用于高风险复发的皮肤鳞状细胞癌的辅助治疗

美股速递
Oct 17

Libtayo® (Cemiplimab) 获欧盟 CHMP 推荐,用于高风险复发的皮肤鳞状细胞癌 (CSCC) 术后及放疗后的辅助治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10